b7-h3 target, car gene modified gdt cell injection
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2021 (NCT05752877)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- CD276 antigenImmunity, passive
CD276 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05731219 | Phase 1 | Sep 26, 2022 | PersonGen BioTherapeutics (Suzhou) Co., Ltd., Zhejiang University |
| NCT05752877 | N/A | May 1, 2021 | Soochow University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PersonGen BioTherapeutics (Suzhou) Co., Ltd. | For profit | 1 | 1 | 1 | 2022 |
| Soochow University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1